HPK1 inhibitors and uses thereof

A compound represented by structural formula (I-2):

• or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein
• A is CR2 or N;
• (i) R is
• wherein the bond connects with the pyrimidine ring;
• each instance of Ra is independently H, F, or Cl;
• Ra1 is independently H, C1-4 alkyl, or C1-4hydroxyalkyl:
• Ra1′ is independently —(CHRaa)kOH, —(CHRaa)kCN, —(CHRaa)kC(O)OR11, —(CHRaa)kC(O)NR11R12, —(CHRaa)kC(O)NR11OR12, —(CHRaa)kC(O)NR11S(═O)2R12, —(CHRaa)kS(═O)2R11, —(CHRaa)kS(═O)2NR11R12, —(CHRaa)kNR11S(═O)2R12, —(CHRaa)k-5-6 membered heteroaryl, or —(CHRaa)kP(═O)R11R12;
• Raa is independently H or C1-3 alkyl optionally substituted with halogen;
• R1 is H, deuterium, halogen, OH, CN, NH2, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, NR11R12, C(O)NR11R12, C(O)C1-6 alkyl, C(O)OC1-6 alkyl, NR11C(O)C1-6 alkyl, phenyl, 5-6 membered heteroaryl, C3-6 cycloalkyl, or 3-7 membered heterocyclyl, wherein the alkyl, alkenyl, alkynyl, alkoxy, phenyl, heteroaryl, cycloalkyl, or heterocyclyl represented by R1 or in the group represented by R1 is optionally substituted with one to three substituents independently selected from the group consisting of halogen, OH, CN, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, and NR11R12;
• or
• (ii) R and R1, together with the carbon atoms to which they are attached, form a ring represented below:
• wherein the bonds connect with the pyrimidine ring;
• each instance of Rb is independently H, deuterium, halogen, OH, CN, NH2, NO2, COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, NR11R12, C(O)NR11R12, C(O)NR11OR12, C(O)NR11S(═O)2R12, C(O)C1-6 alkyl, C(O)OR11, NR11C(O)R12, S(═O)2R11, S(═O)2NR11R12, NR11S(═O)2R12, P(═O)R11R12, C3-6 cycloalkyl, 3-7 membered heterocyclyl, or 5-6 membered heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, or heteroaryl represented by Rb or in the group represented by Rb is optionally substituted with one to three substituents independently selected from the group consisting of halogen, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4haloalkoxy, NR11R12, C(O)NR11R12, C(O)NR11OR12, C(O)NR11S(═O)2R12, C(O)OR11, NR11S(═O)2R12, P(═O)R11R12, S(═O)2R11, S(═O)2NR11R12, and 5-6 membered heteroaryl;
• each instance of Rc is independently phenyl, 5-6 membered monocyclic heterocyclyl having 1 to 3 heteroatoms selected from N and 0;
• 5-6 membered monocyclic heteroaryl having 1 to 3 heteroatoms selected from N and O;
• wherein the phenyl, heterocyclyl, or heteroaryl represented by Rc is optionally substituted with one to three substituents independently selected from the group consisting of halogen, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4haloalkoxy, NR11R12, C(O)NR11R12, and P(O)di-C1-6 alkyl;
• each instance of R2 is independently H, deuterium, halogen, OH, CN, NH2, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, NR11R12, C(O)NR11R12, C(O)C1-6 alkyl, C(O)OC1-6 alkyl, NR11C(O)C1-6 alkyl, P(═O)R11R12, S(═O)2R11, or S(═O)2NR11R12, wherein the alkyl, alkenyl, alkynyl, or alkoxy represented by R2 or in the group represented by R2 is optionally substituted with one to three substituents independently selected from the group consisting of halogen, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, and NR11R12;
• R3 is H, C1-6 alkyl, C(O)C1-6 alkyl, C3-6 cycloalkyl, or 3-7 membered heterocyclyl, wherein the alkyl, cycloalkyl, or heterocyclyl represented by R3 or in the group represented by R3 is optionally substituted with one to three substituents independently selected from the group consisting of halogen, OH, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4haloalkoxy, C3-6 cycloalkyl, 3-7 membered heterocyclyl, and NR11R12;
• each instance of R11 and R12 is independently H or C1-4 alkyl;
• m is 0, 1, 2, or 3;
• and
• k is 0 or 1.